A randomized, placebo‐controlled trial of infliximab plus methotrexate for the treatment of polyarticular‐course juvenile rheumatoid arthritis

…, ED Silverman, Z Balogh, M Henrickson… - … : Official Journal of …, 2007 - Wiley Online Library
Objective To evaluate the safety and efficacy of infliximab in the treatment of juvenile rheumatoid
arthritis (JRA). Methods This was an international, multicenter, randomized, placebo‐…

[PDF][PDF] The tumor-necrosis-factor receptor–associated periodic syndrome: new mutations in TNFRSF1A, ancestral origins, genotype-phenotype studies, and evidence …

…, J Dean, B Athreya, AJ Reginato, M Henrickson… - The American Journal of …, 2001 - cell.com
Mutations in the extracellular domain of the 55-kD tumor-necrosis factor (TNF) receptor (TNFRSF1A),
a key regulator of inflammation, define a periodic-fever syndrome, TRAPS (TNF …

Consensus treatment plans for induction therapy of newly diagnosed proliferative lupus nephritis in juvenile systemic lupus erythematosus

…, A Eichenfield, N Fish, M Henrickson… - Arthritis care & …, 2012 - Wiley Online Library
Objective To formulate consensus treatment plans (CTPs) for induction therapy of newly
diagnosed proliferative lupus nephritis (LN) in juvenile systemic lupus erythematosus (SLE). …

Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis: findings from an open-label …

…, ED Silverman, Z Balogh, M Henrickson… - Annals of the …, 2010 - ard.bmj.com
Objective To assess the long-term efficacy and safety of infliximab plus methotrexate in
juvenile rheumatoid arthritis (JRA). Methods Patients eligible for the open-label extension (OLE, …

Safety and efficacy of intravenous belimumab in children with systemic lupus erythematosus: results from a randomised, placebo-controlled trial

…, M Shishov, AL Boteanu, M Henrickson… - Annals of the …, 2020 - ard.bmj.com
Objectives This ongoing Phase-2, randomised, placebo-controlled, double-blind study
evaluated the efficacy, safety and pharmacokinetics of intravenous belimumab in childhood-onset …

Etanercept treatment in patients with refractory systemic onset juvenile rheumatoid arthritis.

…, G Higgins, D Hummell, I Szer, M Henrickson… - The Journal of …, 2005 - jrheum.org
OBJECTIVE:. To assess the efficacy and safety of etanercept in a large cohort of children with
refractory systemic onset juvenile rheumatoid arthritis (SOJRA). METHODS: Standardized …

[PDF][PDF] Loss-or gain-of-function mutations in ACOX1 cause axonal loss via different mechanisms

…, R Hopkin, J Rodriguez-Smith, M Henrickson… - Neuron, 2020 - cell.com
ACOX1 (acyl-CoA oxidase 1) encodes the first and rate-limiting enzyme of the very-long-chain
fatty acid (VLCFA) β-oxidation pathway in peroxisomes and leads to H 2 O 2 production. …

2010 American College of Rheumatology adult fibromyalgia criteria for use in an adolescent female population with juvenile fibromyalgia

…, A Lynch-Jordan, C Whitacre, M Henrickson… - The Journal of …, 2016 - Elsevier
Objectives To evaluate the utility of the 2010 American College of Rheumatology (ACR) adult
fibromyalgia criteria for use in adolescents with juvenile fibromyalgia (JFM). Study design …

Association of Anti–3‐Hydroxy‐3‐Methylglutaryl‐Coenzyme A Reductase Autoantibodies With DRB1* 07: 01 and Severe Myositis in Juvenile Myositis Patients

…, K Pak, L Barillas‐Arias, M Henrickson… - Arthritis care & …, 2017 - Wiley Online Library
Objective Autoantibodies recognizing 3‐hydroxy‐3‐methylglutaryl‐coenzyme A reductase (HMGCR)
are associated with statin exposure, the HLA allele DRB1*11:01, and necrotizing …

Prolonged efficacy of etanercept in refractory enthesitis-related arthritis.

M Henrickson, A Reiff - The Journal of Rheumatology, 2004 - jrheum.org
OBJECTIVE: For many children enthesitis-related arthritis (ERA) causes substantial morbidity,
and conventional treatments frequently offer limited efficacy. Tumor necrosis factor-alpha (…